Men Getting Older Will Testosterone Keep Him Young?
|
|
|
- Lynn Higgins
- 5 years ago
- Views:
Transcription
1 Men Getting Older Will Testosterone Keep Him Young? Alvin M. Matsumoto, M.D. Associate Director, GRECC V.A. Puget Sound Health Care System Professor, Department of Medicine Division of Gerontology and Geriatric Medicine University of Washington School of Medicine AACE 25 th Annual Meeting May 27, Disclosures Research support AbbVie, GSK Consultation AbbVie, Clarus, Endo, Lilly Royalties UpToDate 2 1
2 Charles Edouard Brown-Séquard Rejuvenating effects of self-injecting aqueous extracts (inactive) from dog and guinea pig testes Age 72 yrs strength expulsion of fecal matters... intellectual labour Brown-Séquard CE, Lancet 2: , Male Hypogonadism Diagnosis Clinical manifestations of androgen deficiency AND consistently low T level Symptoms & signs least x 2, preferably in morning, fasting Symptoms alone or low T level alone hypogonadism Result in over-diagnosis Bhasin S, et al, J Clin Endocrinol Metab 95: ,
3 Percentage Prevalence of Low T Alone vs Low T with 60 Symptoms BLSA Low T only MMAS (Multiple Sx) BACH (Multiple Sx) EMAS (Sexual Sx) 10 0 Overall Age (yrs) Harman SM, et al, J Clin Endocrinol Metab 86: , 2001; Araujo A, et al, J Clin Endocrinol Metab 89: , 2004; Araujo A, et al, J Clin Endocrinol 5 Metab 92: , 2007; Wu FC, et al, N Engl J Med 363: , 2010 Age-Related Hypogonadism Symptoms non-specific Modest T levels may not be hypogonadism Combined 1 o and 2 o hypogonadism 1 o hypogonadism organic (age) Leydig cell number and T response to hcg 2 o hypogonadism functional (comorbidity) Obesity, co-morbid illness, medications FSH and LH normal (2 o most common) or slightly (1 o advanced old age) High prevalence CV and prostate disease 6 3
4 FSH (miu/ml) LH (miu/ml) Longitudinal Changes in Serum LH Levels in Older Men * * Year Morley JE, et al, Metabolism 46: , Longitudinal Changes in Serum FSH Levels in Older Men Year * * * Morley JE, et al, Metabolism 46: ,
5 Causes of Symptoms or Low T Level Other Than Hypogonadism Symptoms & signs not caused by low T level Depression, medications, comorbidities Low T level not caused by hypogonadism Transient T (illness, drugs, malnutrition) Biological T variability (lower T in PM and nonfasting; day-to-day variation 30%) Low SHBG (obesity) total T but normal free T Matsumoto AM, Endocrinol Metab Clin N Am 42: , Performance of Total T to Predict Calculated Free T in Veterans Lower limit Free T Of Men with Low Total T, 62% had Normal Free T n=3672 n=3672 Lower limit Total T Anawalt BD, et al, J Urol 187: ,
6 EMAS Low Free not Total T Associated with Sexual and Physical Symptoms Antonio L, et al, J Clin Endocrinol Metab, 2016 Feb 24 [Epub ahead of print] 11 Cause of Hypogonadism Organic congenital, destructive or structural Not reversible Clinically and biochemically more severe Functional reversible gonadotropin suppression Intact reproductive axis (~functional amenorrhea) More common than organic causes Matsumoto AM, Endocrinol Metab Clin N Am 42: ,
7 Causes of 2 o Hypogonadism Organic Pituitary/hypothalamic tumor Stalk section or disease Hypopituitarism Hemochromatosis Kallmann syndrome, IHH Functional Opioids, CNS-active drugs Glucocorticoids* Prolactin Chronic illness*, wasting Organ failure Malnutrition, morbid obesity Excess exercise Androgens, progestins, estrogens, GnRH agonists Aging?* Nl- LH * Combined Matsumoto AM, Endocrinol Metab Clin N Am 42: , 2013 T GnRH Nl- FSH Sperm Inhibin B 13 Effect of Obesity Onset on Decline in T Levels MMAS Travison T, et al, Eur J Endocrinol 92: ,
8 Longitudinal Δ in Weight vs. Δ in Hormones EMAS Comacho EM, et al, Eur J Endocrinol 168: , Effect of Weight Loss on T Levels Each point = single study Size of point = size of each study Grossmann M, J Clin Endocrinol Metab 96: ,
9 Limitations of Previous T Treatment Trials in Older Men Heterogenous Healthy without symptoms/signs Men with normal T levels Short-term T Rx T levels too low or high Small n s (under-powered) Surrogate, not optimal measures 17 The Testosterone Trials Randomized, double-blind, placebo-controlled trial of T vs. placebo x 1 yr 790 men 65 yrs, symptoms/signs, T 275 ng/dl x 2, low risk prostate cancer 7 coordinated trials (12 sites): Physical function, sexual function, vitality Cognitive function, anemia, cardiovascular, bone T gel 5 g/d adjusted to T ng/dl 18 9
10 51,085 screened The T Trials Screening and Recruitment 4700/21,940 low T on 1 st blood sampling (21%) 1490/2163 low T on 2 nd blood sampling (69%) Overall inclusion by T level 14.7% Cauley JA et al, J Gerontol A Biol Sci Med Sci 70: , The T Trials Total Testosterone in All Men N=790 72±6 years 88% white, 5% black BMI 31±4, 63% BMI > 30 n=395 n=
11 The T Trials Sexual Function Trial N=459 Low libido and DISF-M-II score 20 Partner willing to have sexual activity n=230 n= The Testosterone Trials T vs. Placebo in Sexual Function Trial 1 o in Sexual Function Trial men Moderate sexual activity by PDQ-4 2 o in Sexual Function Trial men Moderate libido by DISF-M-II and erectile function by IIEF 2 o in All T Trials men Moderate sexual activity by PDQ-4 Global impression of improved libido 22 11
12 The Testosterone Trials Physical Function Trial N=387 Difficulty walking or climbing stairs and Gait speed < 1.2 m/sec N=191 N= The Testosterone Trials T vs. Placebo in Physical Function Trial 1 o in Physical Function Trial men No 50 m on 6 minute walk 2 o in All T Trials men Small 50 m and total on 6 minute walk Small physical function by 8 and total score on PF-10 Global impression of improved walking ability 24 12
13 The Testosterone Trials Vitality Trial N=475 Low energy and FACIT-Fatigue score 40 N=236 N= The Testosterone Trials T vs. Placebo in Vitality Trial 1 o in Vitality Trial men No 4 m on FACIT-Fatigue 2 o in Vitality T Trial men Small positive and negative affect by PANAS Small depression symptoms by PHQ-9 2o in All T Trials men Small in FACIT-Fatigue score Global impression of improved energy 26 13
14 The Testosterone Trials T vs. Placebo Adverse Events 27 Low T Levels in Older Men Take Homes Consider other causes of symptoms and low T Depression, medications, comorbidities Transient T, biological T variability, low SHBG Age-related hypogonadism 1 o and 2 o Potentially reversible functional 2 o causes of low T T treatment in older men with hypogonadism Sexual function and may physical function, mood, depressive symptoms (The Testosterone Trials) Effects on cognitive function, cardiovascular disease, bone and anemia forthcoming 28 14
Androgen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital
Androgen deficiency Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Outline Pathological androgen deficiency - Background, causes, interpretation - Indications for treatment Androgen
Hypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.
Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology
Recognizing and Managing Testosterone Deficiency
Recognizing and Managing Testosterone Deficiency J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships
Testosterone Therapy in Men An update
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
PRISM Bruges June Herman Leliefeld Urologist. The Netherlands
PRISM Bruges 25-26 June 2015 Herman Leliefeld Urologist The Netherlands Guidelines EAU 2015: a rich source of Knowledge! Epidemiology/ Aetiology / Pathology Diagnostic evaluation Disease management Follow-Up
6/14/2010. GnRH=Gonadotropin-Releasing Hormone.
Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression
Is T for Me? Testosterone Replacement Therapy in Older Males
Is T for Me? Testosterone Replacement Therapy in Older Males Natalia Malesa, PharmD, MSIS PGY1 Community Pharmacy Resident H-E-B Pharmacy The University of Texas at Austin Objectives At the end of this
Index. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acquired hypogonadism, prevalence of, 165 167 primary, 165 secondary, 167 Adipose tissue, as an organ, 240 241 Adrenal hyperplasia, congenital,
What Is the Low T Syndrome? Is Testosterone Supplementation Safe?
What Is the Low T Syndrome? Is Testosterone Supplementation Safe? UCSF Osher Mini Medical School March 7, 2018 Dolores Shoback, MD Staff Physician SF-VAMC Professor of Medicine, UCSF No disclosures or
Update on diagnosis and complications of adult and elderly male hypogonadism
Hypoandrogenism in the elderly: to treat or not to treat? 12 th Italian AME Meeting; 6 th joint Meeting with AAC Bari november 10th Update on diagnosis and complications of adult and elderly male hypogonadism
Disclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
Hypogonadism in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
Hypogonadism in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017
Testosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E
Testosterone Treatment: Myths Vs Reality Fadi Al-Khayer, M.D, F.A.C.E The Biological Functions of Testosterone in Men Testosterone is essential to the musculoskeletal and metabolic systems throughout a
Prof. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany
Induction of fertility in hypogonadal men Prof. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany Induction of fertility in hypogonadal men Prof.
An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health
An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health KEVIN R. LOUGHLIN MD,MBA Harvard Medical School Boston, MA THE WEAKER SEX-MALES LIFE EXPECTANCY
BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE
Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation
HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY)
HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) DEFECT OF THE REPRODUCTIVE SYSTEM THAT RESULTS IN LACK OF FUNCTION OF THE GONADS (Wikipedia) REDUCTION
ANDROGEN DEFICIENCY/MALE HYPOGONADISM
ANDROGEN DEFICIENCY/MALE HYPOGONADISM 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone (androgen deficiency)
EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE
EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE Matthew Ho, PGY-2 Department of Urologic Sciences University of British Columbia OBJECTIVES 1. Review the characteristics
Testosterone: Current Opinion and Controversy
Testosterone: Current Opinion and Controversy Ravi Kacker, MD Metrowest Urology (508) 655 4422 Medical Office Building at Leonard Morse Hospital Disclosures MHB Labs President and CEO of Drug Development
Outline. Classic Androgen deficiency. Cardiovascular Risk and Testosterone Fact vs Fiction. Professor Robert I McLachlan AM, FRACP, PhD
Health Ed Brisbane Saturday 27 th October 2018 Cardiovascular Risk and Testosterone Fact vs Fiction Professor Robert I McLachlan AM, FRACP, PhD Hudson Institute of Medical Research, Monash University Department
Testosterone Therapy in Men with Hypogonadism
Testosterone Therapy in Men with Hypogonadism (Endocrine Society 2018 Guideline) Ngwe Yin, MD Assistant Clinical Professor of Medicine, UCSF Fresno Medical Education Program Disclosures None Objective
ANDROGEN DEFICIENCY/MALE HYPOGONADISM
Medical Information to Support the Decisions of TUE Committees 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of
Male History, Clinical Examination and Testing
Male History, Clinical Examination and Testing Dirk Vanderschueren, MD, PhD Case Jan is 29 years old and consults for 1 year primary subfertility partner 28 years old and normal gynaecological investigation
Managing Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University
Managing Testosterone Deficiency: A Practical Guide John Grantmyre MD Professor of Urology Dalhousie University 1 2 Case Study #1 A 59-Year-Old Man with Erectile Dysfunction 3 Case History Robert is a
EAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by
TESTOSTERONE DEFINITION
DEFINITION A hormone that is a hydroxyl steroid ketone (C19H28O2) produced especially by the testes or made synthetically and that is responsible for inducing and maintaining male secondary sex characteristics.
Androderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
Developing clinical stage small molecule therapeutics to treat hormonal and reproductive system disorders
Developing clinical stage small molecule therapeutics to treat hormonal and reproductive system disorders Repros Disclaimer Any statements made by the Company that are not historical facts contained in
EAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Limited text update March 2017) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch Introduction Male hypogonadism is a clinical syndrome caused by androgen
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency
ANDROGEN DEFICIENCY Update on Evaluation and Management
ANDROGEN DEFICIENCY Update on Evaluation and Management Kristen Gill Hairston, MD, MPH Associate Professor of Internal Medicine Section of Endocrinology and Metabolism Wake Forest University School of
Reproductive Health and Pituitary Disease
Reproductive Health and Pituitary Disease Janet F. McLaren, MD Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology jmclaren@uabmc.edu Objectives
Testosterone Deficiency Syndrome. Time for Proper Personalised Care
Prof Geoffrey Hackett Good Hope Hospital Sutton Coldfield Testosterone Deficiency Syndrome Time for Proper Personalised Care BSSM Testosterone Guidelines 2017 www.bssm.org.uk Recommendations Diagnosis
Advisory Committee Industry Briefing Document. Testosterone Replacement Therapy
Advisory Committee Industry Briefing Document Testosterone Replacement Therapy Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting
Disclosures. Faculty 3/5/18. Testosterone, the FDA and CVD Risk Controversies. Matt Rosenberg, MD Director of Mid-Michigan Health Centers Jackson, MI
Testosterone, the FDA and CVD Risk Controversies Faculty Matt Rosenberg, MD Director of Mid-Michigan Health Centers Jackson, MI 2 Disclosures Matt Rosenberg, MD serves on the advisory board for Bayer,
66 M with erectile dysfunction and abnormal labs RAJESH JAIN ENDORAMA 10/29/2015
66 M with erectile dysfunction and abnormal labs RAJESH JAIN ENDORAMA 10/29/2015 HPI 66 M presenting as a referral for erectile dysfunction and abnormal labs Has been seeing a facility specializing in
GUIDELINES ON MALE HYPOGONADISM
GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by androgen
Alternative management of hypogonadism Tamoxifen. Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY
Alternative management of hypogonadism Tamoxifen Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY eajannini@gmail.com What hypogonadism is? What hypogonadism is? It is an empty glass The two
Late onset hypogonadism
Late onset hypogonadism Farrukh Javid Male Menopause Clinical AND biochemical syndrome Testosterone levels decline by 0.4-3% per year after the age of 30, as opposed to the more rapid decline that occurs
A dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male
Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.
R. Charles Welliver, Jr.,* Herbert J. Wiser, Robert E. Brannigan, Kendall Feia, Manoj Monga and Tobias S. K ohler
Sexual Function/Infertility Validity of Midday Total Testosterone Levels in Older Men with Erectile Dysfunction R. Charles Welliver, Jr.,* Herbert J. Wiser, Robert E. Brannigan, Kendall Feia, Manoj Monga
TUE Physician Guidelines Medical Information to Support the Decisions of TUE Committees MALE HYPOGONADISM MALE HYPOGONADISM
1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone (testosterone deficiency) and in some instances normal
GUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde
GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients
Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008
ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN
International Society for Sexual Medicine - www.issm.info ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN Version: September 2015 What is testosterone deficiency? Testosterone deficiency
Diagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ)
Diagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ) Alvaro Morales CM MD, Richard A. Bebb MD, Priya Manjoo MD MSc, Peter Assimakopoulos MD, John
Diseases / conditions affecting the steroid profile in blood
Athlete Biological Passport Symposion Rome, Nov. 5 7, 2018 Diseases / conditions affecting the steroid profile in blood Eberhard Nieschlag Centre of Reproductive Medicine & Andrology University Hospital
HORMONE THERAPY IN AGING MALE ATHLETES
DISCLOSURES HORMONE THERAPY IN AGING MALE ATHLETES No relevant affiliations or financial interests When, Why and is it Safe? OBJECTIVES Summarize the benefits of optimizing hormone balance Examine the
Late Onset Hypogonadism. Toh Charng Chee Hospital Selayang
Late Onset Hypogonadism Toh Charng Chee Hospital Selayang Introduction Although suppressed serum testosterone (T) is common in ageing men, only a small proportion of them develop the genuine syndrome of
Treatment of the Young Hypogonadal Male
Treatment of the Young Hypogonadal Male Paul J. Turek MD, FACS, FRSM Director, The Turek Clinic Beverly Hills and San Francisco, CA Learning Objectives At the conclusion of this presentation, participants
Hd Hydroxylase. Cholesterol. 17-OH Pregnenolne DHEA Andrstendiol. Pregnenolone. 17-OH Progestrone. Androstendione. Progestrone.
PATHOPHISIOLOGY OF SEX HORMONES R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty CHOLESTEROL IS THE PRECURSOR OF STERIOD HORMONES Cholesterol Pregnenolone 17-OH 17βHSD Pregnenolne DHEA
TUE Application for Testosterone Physician Worksheet
TUE Application for Testosterone Physician Worksheet Attention Physicians - USADA will not process Therapeutic Use Exemptions (TUE) for the use of testosterone unless all of the requirements for documentation
Sexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist
Sexual dysfunction of chronic kidney disease Razieh salehian.md psychiatrist Disturbances in sexual function are a common feature of chronic renal failure. Sexual dysfunction is inversely associated with
Assessment and management of male androgen disorders: an update
Irene Chan Mark Ng Tang Fui Jeffrey D Zajac Mathis Grossmann Assessment and management of male androgen disorders: an update Background Male hypogonadism, caused by intrinsic pathology of the hypothalamic
Lessons From the Testosterone Trials
Lessons From the Testosterone Trials Peter J Snyder, 1 Shalender Bhasin, 2 * Glenn R. Cunningham, 3 * Alvin M. Matsumoto, 4 * Alisa J. Stephens-Shields, 5 * Jane A. Cauley, 6 Thomas M. Gill, 7 Elizabeth
5/7/2013. Patrick Nolan, DO, FACE
Patrick Nolan, DO, FACE Patient: T.W. 83 year old male 9/18/2012 AM sudden onset of Vertigo ER visit Had MRI, some labs Home on Zofran and medicines Complete resolution of sx after 2 days MRI chronic sinus
Late onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital
Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,
The association of time of day and serum testosterone concentration in a large screening population
Original Article TIME OF DAY AD SERUM TESTOSTEROE LEVEL I A LARGE SCREEIG POPULATIO CRAWFORD et al. Authors from the USA reviewed semen samples for their ational Prostate Cancer Awareness screening programme.
Point-Counterpoint: Late Onset Hypogonadism (LOH)
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
High and Low GH: an update of diagnosis and management of GH disorders
High and Low GH: an update of diagnosis and management of GH disorders Georgia Chapter-AACE 2017 Laurence Katznelson, MD Professor of Medicine and Neurosurgery Associate Dean of Graduate Medical Education
Basics of Male Libido: Dysfunction & Treatment. Ripu Hundal MD FACE First State Endocrinology Newark, DE
Basics of Male Libido: Dysfunction & Treatment Ripu Hundal MD FACE First State Endocrinology Newark, DE Sexual Hormones Steroid hormones Commonly referred to as male sex hormones and female sex hormones,
Risk of renal side effects with ADT. E. David Crawford University of Colorado, Aurora, CO, USA
Risk of renal side effects with ADT E. David Crawford University of Colorado, Aurora, CO, USA ADT: A key treatment for advanced prostate cancer John Hunter 1780-castration 1904: First RP 1938: Acid Phos.
Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
SPECIAL FEATURE Clinical Practice Guideline Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline Shalender Bhasin, Glenn R. Cunningham, Frances
Hormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
How to treat: TRT modalities and formulations
How to treat: TRT modalities and formulations Paul PIETTE, PharmD Senior Research Fellow Clinique Antoine Depage - Belgium ppiette@besins-healthcare.com Bruges 2014, May 15 th Testosterone-replacement
Prevalence of hypogonadism in males aged at least 45 years: the HIM study
ORIGINAL PAPER doi: 10.1111/j.1742-1241.2006.00992.x Prevalence of hypogonadism in males aged at least 45 years: the HIM study T. MULLIGAN, 1 M. F. FRICK, 2 Q. C. ZURAW, 2 A. STEMHAGEN, 2 C. MCWHIRTER
abstract n engl j med 374;7 nejm.org February 18,
The new england journal of medicine established in 1812 February 18, 2016 vol. 374 no. 7 Effects of Testosterone Treatment in Older Men P.J. Snyder, S. Bhasin, G.R. Cunningham, A.M. Matsumoto, A.J. Stephens
Natural Hormones Replacement An Evidence and Practice Based Approach
Natural Hormones Replacement An Evidence and Practice Based Approach Andres Ruiz, PharmD, MSc, FACA President/Partner Stonegate Pharmacy PRESENTED BY THE AMERICAN COLLEGE OF APOTHECARIES 2830 SUMMER OAKS
43 year old man with low libido. Katie Stanley, MD August 16, 2012
43 year old man with low libido Katie Stanley, MD August 16, 2012 HPI 43 yo M with history of heroin addiction on methadone maintenance Reported low libido to PCP PCP checked testosterone and found to
PITUITARY: JUST THE BASICS PART 2 THE PATIENT
PITUITARY: JUST THE BASICS PART 2 THE PATIENT DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none Steps taken to review and
Update on Androgen Deficiency. Acknowledgments. Curatio PowerPoint TemplateControversies in Male Hypogonadism Bradley D.
The General Practice Education Day Healthed / Generation Next August 22 nd Sydney Update on Androgen Deficiency Robert I. McLachlan, FRACP, PhD Director, Andrology Australia Principal Research Fellow,
Why Do We Treat Obesity? Organ-Specific, Hormonal, and Biomechanical Complications
Why Do We Treat Obesity? Organ-Specific, Hormonal, and Biomechanical Complications Organ-Specific, Hormonal, and Biomechanical Complications Gallbladder Disease 3 The Paradox of Obesity and Gallbladder
Didactic Series. Hypogonadism and HIV. Daniel Lee, MD UCSD Medical Center, Owen Clinic July 28, 2016
Didactic Series Hypogonadism and HIV Daniel Lee, MD UCSD Medical Center, Owen Clinic July 28, 2016 This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department
Testosterone Replacement Therapy for Hypogonadism: Learning Objectives. What Is the Evidence? Is It Safe? Case Study. Case Study contd.
4 4:4pm Testosterone Therapy: Examining the Evidence SPEAKER Culley Carson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Culley Carson, MD: Consultant
An Evidence-based Review of Clinical Trial Data
An Evidence-based Review of Clinical Trial Data Karen K. Miller, MD Massachusetts General Hospital Harvard Medical School Boston, MA 1 Rationale for Investigating Androgen Administration in Women: Data
Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products.
Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products. 3-30-2015; web William E. Winter, MD University of Florida Departments of Pathology
An Update on Men s Health and Sexual Function
An Update on Men s Health and Sexual Function Lawrence Jenkins, MD, MBA Assistant Professor Clinical Department of Urology The Ohio State University Wexner Medical Center Outline Testosterone Deficiency
Reproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
Hormone Replacement Therapy
Hormone Replacement Therapy What Role Should It Play With Our Patients? Noel R. Williams MD, FACOG TESTOSTERONE FOR MEN: SALVATION OR SNAKE OIL? Definition Male hypogonadism means the testicles don't produce
Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA
Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA Prevailing context Increase number of men who are potential candidates for Testosterone Replacement Therapy
Hormones of brain-testicular axis
(Hormone Function) Hormones of brain-testicular axis anterior pituitary drives changes during puberty controlled by GnRH from hypothalamus begins to secrete FSH, LH LH targets interstitial endocrinocytes
Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes
Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes E. David Crawford, M.D. Professor of Surgery/ Urology/ Radiation Oncology University of Colorado Greetings from Colorado Disclosures Consultant:
Why is my body not changing? Conflicts of interest. Overview 11/9/2015. None
Why is my body not changing? Murthy Korada Pediatrician, Pediatric Endocrinologist Ridge Meadows Hospital Surrey Memorial Hospital None Conflicts of interest Overview Overview of normal pubertal timing
HHS Public Access Author manuscript Int J Impot Res. Author manuscript; available in PMC 2015 September 01.
Testosterone Therapy and Mortality Risk Michael L. Eisenberg, MD 1, Shufeng Li, MS 2, Danielle Herder, MD 3, Dolores J. Lamb, PhD 4, and Larry I. Lipshultz, MD 4 1 Assistant Professor, Departments of Urology
MALE HYPOGONADISM: CHOOSING THE APPROPRIATE THERAPY. Michael S. Irwig, M.D. Director, Center for Andrology Division of Endocrinology & Metabolism
MALE HYPOGONADISM: CHOOSING THE APPROPRIATE THERAPY Michael S. Irwig, M.D. Director, Center for Andrology Division of Endocrinology & Metabolism Disclosures Aromatase inhibitors & clomiphene citrate are
The CATCH checklist to investigate adult-onset hypogonadism
ISSN: 2047-2919 REVIEW ARTICLE Correspondence: Giuseppe Defeudis, Department of Experimental Medicine, Sapienza University of Rome, Italy and Unit of Endocrinology and Diabetes, Department of Medicine,
PERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
GONADAL FUNCTION: An Overview
GONADAL FUNCTION: An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences Clinical Biochemistry BMLS III & BDS IV VJ Temple 1 What are the Steroid hormones?
Male hypogonadism & testosterone replacement therapy
Male hypogonadism & testosterone replacement therapy Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported
Testosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone Oral Buccal Nasal Description
Testosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone Oral Buccal Nasal
Mechanism: How ADT accelerates CVD?
Mechanism: How ADT accelerates CVD? Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials and conflict of interests Professor
Best Practices to Improve Patient Outcomes
Best Practices Pearls Practical Primary Care Strategies for Diagnosing and Managing Hypogonadism in Men Utilize lab testing in appropriate patients who have complaints consistent with the often subtle
10.7 The Reproductive Hormones
10.7 The Reproductive Hormones December 10, 2013. Website survey?? QUESTION: Who is more complicated: men or women? The Female Reproductive System ovaries: produce gametes (eggs) produce estrogen (steroid
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline
CLINICAL PRACTICE GUIDELINE Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline Shalender Bhasin, 1 Juan P. Brito, 2 Glenn R. Cunningham, 3 Frances J. Hayes,
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
Preparing for the road ahead. LEARN MORE ABOUT these 5 risks
Preparing for the road ahead LEARN MORE ABOUT these 5 risks to A MAN S health 3 4 5 2 6 1 7 0 8 9 WHY DOES IT SEEM LIKE SOME MEN TAKE BETTER CARE OF THEIR CARS THAN THEIR OWN HEALTH? When the check engine
Testosterone and PDE5 inhibitors in the aging male
Testosterone and PDE5 inhibitors in the aging male Francesco Romanelli Department of Experimental Medicine Medical Pathophysiology, Food Science and Endocrinology Section Sapienza University of Rome 3005